Assignee
BIOATLA INC
US·18 granted patents·24 pending applications·16 citations·filing 2016–2025
Top patents by PatentIndex Score
42 records- 0196US11773509B2Conditionally active polypeptides and methods of generating themBIOATLA INC·Filed 2021·Granted Oct 3, 2023·2 cites·19 claims
- 0295US11897959B2Anti-AXL antibodies, antibody fragments and their immunoconjugates and uses thereofBIOATLA INC·Filed 2021·Granted Feb 13, 2024·2 cites·20 claims
- 0393US12110611B2Conditionally active biological proteinsBIOATLA INC·Filed 2022·Granted Oct 8, 2024·1 cites·8 claims
- 0493US11851499B2Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2020·Granted Dec 26, 2023·2 cites·27 claims
- 0591US11472876B2Conditionally active polypeptidesBIOATLA INC·Filed 2016·Granted Oct 18, 2022·4 cites·11 claims
- 0690US11584927B2Conditionally active chimeric antigen receptors for modified T-cellsBIOATLA INC·Filed 2018·Granted Feb 21, 2023·3 cites·14 claims
- 0789US2023332135A1Mirac proteinsBIOATLA INC·Filed 2023·Application pending·0 cites
- 0889US2026053904A1Conditionally active anti-epcam antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2025·Application pending·0 cites
- 0989US2024263354A1Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hostsBIOATLA INC·Filed 2024·Application pending·0 cites
- 1088US2024417886A1Conditionally active biological proteinsBIOATLA INC·Filed 2024·Application pending·0 cites
- 1187US12311032B2Anti-Ror2 antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2023·Granted May 27, 2025·0 cites·24 claims
- 1285US12427347B2Conditionally active anti-EpCAM antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2023·Granted Sep 30, 2025·0 cites·18 claims
- 1385US11718844B2Mirac proteinsBIOATLA INC·Filed 2017·Granted Aug 8, 2023·1 cites·18 claims
- 1483US2023183679A1Conditionally active chimeric antigen receptors for modified t-cellsBIOATLA INC·Filed 2022·Application pending·0 cites
- 1582US2023374702A1Method for preparing a conditionally active antibody or antibody fragmentBIOATLA INC·Filed 2023·Application pending·0 cites
- 1681US12595592B2Comprehensive monoclonal antibody generationBIOATLA INC·Filed 2022·Granted Apr 7, 2026·0 cites·32 claims
- 1780US2024199746A1Anti-axl antibodies, antibody fragments and their immunoconjugates and uses thereofBIOATLA INC·Filed 2024·Application pending·0 cites
- 1878US11879011B2Anti-ROR2 antibodies, antibody fragments, their immunoconjucates and uses thereofBIOATLA INC·Filed 2021·Granted Jan 23, 2024·0 cites·24 claims
- 1978US11542332B2Anti-CTLA4 antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2019·Granted Jan 3, 2023·1 cites·19 claims
- 2078US2024141035A1Anti-Il-22 Antibodies, Antibody Fragments,Their Immunoconjugates And Uses ThereofBIOATLA INC·Filed 2023·Application pending·0 cites
- 2178US2022325002A1Express humanization of antibodiesBIOATLA INC·Filed 2022·Application pending·0 cites
- 2277US2025170264A1Anti-ror2 antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2025·Application pending·0 cites
- 2372US11976381B2Simultaneous, integrated selection and evolution of antibody/protein performance and expression in production hostsBIOATLA INC·Filed 2021·Granted May 7, 2024·0 cites·13 claims
- 2472US2022341941A1Proteins targeting orthologsBIOATLA INC·Filed 2022·Application pending·0 cites
- 2571US11639365B2Methods of protein evolutionBIOATLA INC·Filed 2020·Granted May 2, 2023·0 cites·20 claims
- 2670US11396717B2Comprehensive monoclonal antibody generationBIOATLA INC·Filed 2020·Granted Jul 26, 2022·0 cites·31 claims
- 2770US11396556B2Express humanization of antibodiesBIOATLA INC·Filed 2020·Granted Jul 26, 2022·0 cites·22 claims
- 2870US2022403024A1Conditionally active polypeptidesBIOATLA INC·Filed 2022·Application pending·0 cites
- 2969US2022282399A1Protein therapeutics for treatment of senescent cellsBIOATLA INC·Filed 2022·Application pending·0 cites
- 3067US11834472B2Anti-IL-22 antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2019·Granted Dec 5, 2023·0 cites·29 claims
- 3165US2021355203A1Conditionally active chimeric antigen receptors for modified t-cellsBIOATLA INC·Filed 2021·Application pending·0 cites
- 3264US2023192858A1ANTI-CTLA4 Antibodies, Antibody Fragments, Their Immunoconjugates and Uses ThereofBIOATLA INC·Filed 2022·Application pending·0 cites
- 3364US2025161472A1Cancer treatment with a conditionally active anti-ror2 antibody-drug conjugateBIOATLA INC·Filed 2023·Application pending·0 cites
- 3463US2024400659A1Conditionally active proteins for neurodegenerative diseasesBIOATLA INC·Filed 2022·Application pending·0 cites
- 3558US2024044046A1Protein therapeutics for treatment of senescent cellsBIOATLA INC·Filed 2023·Application pending·0 cites
- 3658US2025276075A1Methods of treating axl-expressing cancers with anti-axl antibodies, antibody fragments and their immunoconjugatesBIOATLA INC·Filed 2021·Application pending·0 cites
- 3755US2023242662A1Conditionally active anti-cd46 antibodies, antibody fragments, their immunoconjugates and uses thereofBIOATLA INC·Filed 2021·Application pending·0 cites
- 3855US2023109218A1Conditionally Active Anti-Her2 Antibodies, Antibody Fragments Their Immunoconjugates And Uses ThereofBIOATLA INC·Filed 2021·Application pending·0 cites
- 3954US12473360B2Multi-specific antibody constructsBIOATLA INC·Filed 2019·Granted Nov 18, 2025·0 cites·22 claims
- 4054US2021230221A1Protein therapeutics for treatment of senescent cellsBIOATLA INC·Filed 2018·Application pending·0 cites
- 4153US2023235054A1Conditionally active anti-nectin-4 antibodiesBIOATLA INC·Filed 2021·Application pending·0 cites
- 4250US2021309742A1CONDITIONALLY ACTIVE PROTEINS WITH pH SELECTIVITYBIOATLA INC·Filed 2019·Application pending·0 cites
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →